76
|
Zhang L, Yin FF, Li T, Teng X, Xiao H, Harris W, Ren L, Kong FMS, Ge H, Mao R, Cai J. Multi-contrast four-dimensional magnetic resonance imaging (MC-4D-MRI): Development and initial evaluation in liver tumor patients. Med Phys 2021; 48:7984-7997. [PMID: 34706072 DOI: 10.1002/mp.15314] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2020] [Revised: 07/15/2021] [Accepted: 10/06/2021] [Indexed: 12/25/2022] Open
Abstract
PURPOSE To develop a novel multi-contrast four-dimensional magnetic resonance imaging (MC-4D-MRI) technique that expands single image contrast 4D-MRI to a spectrum of native and synthetic image contrasts and to evaluate its feasibility in liver tumor patients. METHODS AND MATERIALS The MC-4D-MRI technique integrates multi-parametric MRI fusion, 4D-MRI, and deformable image registration (DIR) techniques. The fusion technique consists of native MRI as input, image pre-processing, fusion algorithm, adaptation, and fused multi-contrast MRI as output. Four-dimensional deformation vector fields (4D-DVF) were generated from an original T2/T1-w 4D-MRI by deforming end-of-inhalation (EOI) to nine other phase volumes via DIR. The 4D-DVF were applied to multi-contrast MRI to generate a spectrum of 4D-MRI in different image contrasts. The MC-4D-MRI technique was evaluated in five liver tumor patients on tumor contrast-to-noise ratio (CNR), internal target volume (ITV) contouring consistency, diaphragm motion range, and tumor motion trajectory; and in digital anthropomorphic phantoms on 4D-DIR introduced errors in tumor motion range, centroid location, extent, and volume. RESULTS MC-4D-MRI consisting of 4D-MRIs in native image contrasts (T1-w, T2-w, and T2/T1-w) and synthetic image contrasts, such as tumor-enhanced contrast (TEC) were generated in five liver tumor patients. Patient tumor CNR increased from 2.6 ± 1.8 in the T2/T1-w MRI, to -4.4 ± 2.4, 6.6 ± 3.0, and 9.6 ± 3.9 in the T1-w, T2-w, and TEC MRI, respectively. Patient ITV inter-observer mean Dice similarity coefficient (mDSC) increased from 0.65 ± 0.10 in the original T2/T1-w 4D-MRI, to 0.76 ± 0.14, 0.77 ± 0.12, and 0.86 ± 0.05 in the T1-w, T2-w, and TEC 4D-MRI, respectively. Patient diaphragm motion range absolute differences between the three new 4D-MRIs and original T2/T1-w 4D-MRI were 1.2 ± 1.3, 0.3 ± 0.7, and 0.5 ± 0.5 mm, respectively. Patient tumor displacement phase-averaged absolute differences between the three 4D-MRIs and the original 4D-MRI were 0.72 ± 0.33, 0.62 ± 0.54, and 0.74 ± 0.43 mm in the superior-inferior (SI) direction, and 0.59 ± 0.36, 0.51 ± 0.30, and 0.50 ± 0.24 mm in the anterior-posterior (AP) direction, respectively. In the digital phantoms, phase-averaged absolute tumor centroid shift caused by the 4D-DIR were at or below 0.5 mm in SI, AP, and left-right (LR) directions. CONCLUSION We developed an MC-4D-MRI technique capable of expanding single image contrast 4D-MRI along a new dimension of image contrast. Initial evaluations in liver tumor patients showed enhancements in image contrast variety, tumor contrast, and ITV contouring consistencies using MC-4D-MRI. The technique might offer new perspectives on the image contrast of MRI and 4D-MRI in MR-guided radiotherapy.
Collapse
|
77
|
Acharya UA, Aidala C, Akiba Y, Alfred M, Andrieux V, Apadula N, Asano H, Azmoun B, Babintsev V, Bandara NS, Barish KN, Bathe S, Bazilevsky A, Beaumier M, Belmont R, Berdnikov A, Berdnikov Y, Bichon L, Blankenship B, Blau DS, Bok JS, Brooks ML, Bryslawskyj J, Bumazhnov V, Campbell S, Canoa Roman V, Cervantes R, Chi CY, Chiu M, Choi IJ, Choi JB, Citron Z, Connors M, Corliss R, Corrales Morales Y, Cronin N, Csanád M, Csörgő T, Danley TW, Daugherity MS, David G, DeBlasio K, Dehmelt K, Denisov A, Deshpande A, Desmond EJ, Dion A, Dixit D, Do JH, Drees A, Drees KA, Durham JM, Durum A, Enokizono A, En'yo H, Esha R, Esumi S, Fadem B, Fan W, Feege N, Fields DE, Finger M, Finger M, Fitzgerald D, Fokin SL, Frantz JE, Franz A, Frawley AD, Fukuda Y, Gal C, Gallus P, Garg P, Ge H, Giles M, Giordano F, Goto Y, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Guragain H, Hachiya T, Haggerty JS, Hahn KI, Hamagaki H, Hamilton HF, Han SY, Hanks J, Harvey M, Hasegawa S, Haseler TOS, He X, Hemmick TK, Hill JC, Hill K, Hodges A, Hollis RS, Homma K, Hong B, Hoshino T, Hotvedt N, Huang J, Huang S, Imai K, Inaba M, Iordanova A, Isenhower D, Ivanishchev D, Jacak BV, Jezghani M, Ji Z, Jiang X, Johnson BM, Jouan D, Jumper DS, Kang JH, Kapukchyan D, Karthas S, Kawall D, Kazantsev AV, Khachatryan V, Khanzadeev A, Khatiwada A, Kim C, Kim EJ, Kim M, Kincses D, Kingan A, Kistenev E, Klatsky J, Kline P, Koblesky T, Kotov D, Kudo S, Kurgyis B, Kurita K, Kwon Y, Lajoie JG, Larionova D, Lebedev A, Lee S, Lee SH, Leitch MJ, Leung YH, Lewis NA, Li X, Lim SH, Liu MX, Loggins VR, Lökös S, Loomis DA, Lovasz K, Lynch D, Majoros T, Makdisi YI, Makek M, Manko VI, Mannel E, McCumber M, McGaughey PL, McGlinchey D, McKinney C, Mendoza M, Mignerey AC, Milov A, Mishra DK, Mitchell JT, Mitrankov I, Mitrankova M, Mitsuka G, Miyasaka S, Mizuno S, Mondal MM, Montuenga P, Moon T, Morrison DP, Mulilo B, Murakami T, Murata J, Nagai K, Nagashima K, Nagashima T, Nagle JL, Nagy MI, Nakagawa I, Nakano K, Nattrass C, Nelson S, Niida T, Nouicer R, Novák T, Novitzky N, Nukazuka G, Nyanin AS, O'Brien E, Ogilvie CA, Orjuela Koop JD, Osborn JD, Oskarsson A, Ottino GJ, Ozawa K, Pantuev V, Papavassiliou V, Park JS, Park S, Pate SF, Patel M, Peng W, Perepelitsa DV, Perera GDN, Peressounko DY, PerezLara CE, Perry J, Petti R, Phipps M, Pinkenburg C, Pisani RP, Potekhin M, Pun A, Purschke ML, Radzevich PV, Ramasubramanian N, Read KF, Reynolds D, Riabov V, Riabov Y, Richford D, Rinn T, Rolnick SD, Rosati M, Rowan Z, Runchey J, Safonov AS, Sakaguchi T, Sako H, Samsonov V, Sarsour M, Sato S, Schaefer B, Schmoll BK, Sedgwick K, Seidl R, Sen A, Seto R, Sexton A, Sharma D, Sharma D, Shein I, Shibata TA, Shigaki K, Shimomura M, Shioya T, Shukla P, Sickles A, Silva CL, Silvermyr D, Singh BK, Singh CP, Singh V, Slunečka M, Smith KL, Snowball M, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Stankus PW, Stoll SP, Sugitate T, Sukhanov A, Sumita T, Sun J, Sun Z, Sziklai J, Tanida K, Tannenbaum MJ, Tarafdar S, Taranenko A, Tarnai G, Tieulent R, Timilsina A, Todoroki T, Tomášek M, Towell CL, Towell RS, Tserruya I, Ueda Y, Ujvari B, van Hecke HW, Velkovska J, Virius M, Vrba V, Vukman N, Wang XR, Watanabe YS, Wong CP, Woody CL, Xu C, Xu Q, Xue L, Yalcin S, Yamaguchi YL, Yamamoto H, Yanovich A, Yoo JH, Yoon I, Yu H, Yushmanov IE, Zajc WA, Zelenski A, Zharko S, Zou L. Probing Gluon Spin-Momentum Correlations in Transversely Polarized Protons through Midrapidity Isolated Direct Photons in p^{↑}+p Collisions at sqrt[s]=200 GeV. PHYSICAL REVIEW LETTERS 2021; 127:162001. [PMID: 34723614 DOI: 10.1103/physrevlett.127.162001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/01/2021] [Revised: 07/26/2021] [Accepted: 08/10/2021] [Indexed: 06/13/2023]
Abstract
Studying spin-momentum correlations in hadronic collisions offers a glimpse into a three-dimensional picture of proton structure. The transverse single-spin asymmetry for midrapidity isolated direct photons in p^{↑}+p collisions at sqrt[s]=200 GeV is measured with the PHENIX detector at the Relativistic Heavy Ion Collider (RHIC). Because direct photons in particular are produced from the hard scattering and do not interact via the strong force, this measurement is a clean probe of initial-state spin-momentum correlations inside the proton and is in particular sensitive to gluon interference effects within the proton. This is the first time direct photons have been used as a probe of spin-momentum correlations at RHIC. The uncertainties on the results are a 50-fold improvement with respect to those of the one prior measurement for the same observable, from the Fermilab E704 experiment. These results constrain gluon spin-momentum correlations in transversely polarized protons.
Collapse
|
78
|
Xu G, Bu S, Wang X, Ge H. MiR-122 radiosensitize hepatocellular carcinoma cells by suppressing cyclin G1. Int J Radiat Biol 2021; 98:11-17. [PMID: 34623217 DOI: 10.1080/09553002.2021.1987561] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
PURPOSE Emerging evidence has shown that radiotherapy is an effective treatment for hepatocellular carcinoma (HCC), Micro(mi)RNAs are involved in regulating radiosensitivity in many cancers. MiR-122 accounts for approximately 70% of all cloned miRNAs in the liver, but there are few reports about whether it is involved in regulating of radiosensitivity in HCC cells. MATERIALS AND METHODS HCC cells (HepG2 and Huh7) overexpressing miR-122 were constructed by transfecting them with lentiviral-miR-122. Then, their proliferation ability was analyzed by the MTT, and colony formation assays and a xenograft tumor model was used to detect their radiosensitivity. The expression of cyclin G1 mRNA and protein was detected by the quantitative real-time polymerase chain reaction and western blotting, respectively. RESULTS Overexpression of miR-122 inhibited the proliferation of, and radiosensitized HCC cells. Cyclin G1 mRNA and protein level were suppressed in HepG2 tumors overexpression miR-122. CONCLUSION MiR-122 may be useful as a potential radiosensitizer for HCC, and its mechanism is related to the regulation of cyclin G1.
Collapse
|
79
|
Liu Y, Liu J, Tan Z, Jiang X, Wang L, Lu Y, Fu X, Song Q, Zhao L, Yuan S, Bi N, Xu Y, Zhu Z, Zhu G, Li J, Xie C, Ma X, Xiao G, Ge H, Liu H, Zhao J, Liang J, Shen Q, Xu Q, Liu R, Zhou S, Kong W, Zhong W, Jin X, Wang Y, Jiang Y, Fu Z, Xie Y, Cai J, Li Z, Machtay M, Curran W, Kong F. P29.05 Gross Tumor Volume Contouring Variations in Radiation Therapy of Non-Small Cell Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
80
|
Bi N, Hu X, Zhao K, Yang Y, Zhang L, E M, Cao J, Ge H, Zhu X, Zhao L, Di Y, Jiang W, Ran J, Zhang H, Zhang T, Shen W, Deng C, Hu C, Chen M, Wang L. P64.04 Hypo-Fractionated Versus Conventionally Fractionated Radiotherapy for Patients with LS-SCLC: An Open-Label, Randomized, Phase 3 Trial. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.675] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
81
|
Liu J, Jiang X, Tan Z, Li Z, Wang Y, Xie Y, Cai J, Zhu G, Li J, Xie C, Ma X, Xiao G, Liu H, Ge H, Zhao J, Liang J, Shen Q, Xu Q, Liu R, Zhou S, Zhong W, Kong W, Jiang Y, Xu Y, Fu Z, Liu Y, Zhu Z, Bi N, Yuan S, Zhao L, Song Q, Lu Y, Fu X, Wang L, Machtay M, Curran W, Kong F. P29.03 Thoracic Organs at Risk (OARs) Contouring Variations and Consensus in Radiation Therapy for Non-Small Cell Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
82
|
Li B, Chen J, Guo W, Mao R, Zheng X, Cheng X, Cui T, Lou Z, Wang T, Li D, Tao H, Lei H, Ge H. Improvement Using Planomics Features on Prediction and Classification of Patient-Specific Quality Assurance Using Head and Neck Volumetric Modulated Arc Therapy Plan. Front Neurosci 2021; 15:744296. [PMID: 34658779 PMCID: PMC8517188 DOI: 10.3389/fnins.2021.744296] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Accepted: 08/17/2021] [Indexed: 11/30/2022] Open
Abstract
Purpose: This study aimed to evaluate the utility of a new plan feature (planomics feature) for predicting the results of patient-specific quality assurance using the head and neck (H&N) volumetric modulated arc therapy (VMAT) plan. Methods: One hundred and thirty-one H&N VMAT plans in our institution from 2019 to 2021 were retrospectively collected. Dosimetric verification for all plans was carried out using the portal dosimetry system integrated into the Eclipse treatment planning system based on the electronic portal imaging devices. Gamma passing rates (GPR) were analyzed using three gamma indices of 3%/3 mm, 3%/2 mm, and 2%/2 mm with a 10% dose threshold. Forty-eight conventional features affecting the dose delivery accuracy were used in the study, and 2,476 planomics features were extracted based on the radiotherapy plan file. Three prediction and classification models using conventional features (CF), planomics features (PF), and hybrid features (HF) combining two sets of features were constructed by the gradient boosting regressor (GBR) and Ridge classifier for each GPR of 3%/3 mm, 3%/2 mm, and 2%/2 mm, respectively. The absolute prediction error (APE) and the area under the curve (AUC) were adopted for assessing the performance of prediction and classification models. Results: In the GPR prediction, the average APE of the models using CF, PF, and HF was 1.3 ± 1.2%/3.6 ± 3.0%, 1.7 ± 1.5%/3.8 ± 3.5%, and 1.1 ± 1.0%/4.1 ± 3.1% for 2%/2 mm; 0.7 ± 0.6%/2.0 ± 2.0%, 1.0±1.1%/2.2 ± 1.8%, and 0.6 ± 0.6%/2.2 ± 1.9% for 3%/2 mm; and 0.4 ± 0.3%/1.2 ± 1.2%, 0.4±0.5%/1.3 ± 1.0%, and 0.3±0.3%/1.2 ± 1.1% for 3%/3 mm, respectively. In the regression prediction, three models give a similar modeling performance for predicting the GPR. The classification results were 0.67 ± 0.03/0.66 ± 0.07, 0.77 ± 0.03/0.73 ± 0.06, and 0.78 ± 0.02/0.75 ± 0.04 for 3%/3 mm, respectively. For 3%/2 mm, the AUCs of the training and testing cohorts were 0.64 ± 0.03/0.62 ± 0.07, 0.70 ± 0.03/0.67 ± 0.06, and 0.75 ± 0.03/0.71 ± 0.07, respectively, and for 2%/2 mm, the average AUCs of the training and testing cohorts were 0.72 ± 0.03/0.72 ± 0.06, 0.78 ± 0.04/0.73 ± 0.07, and 0.81 ± 0.03/0.75 ± 0.06, respectively. In the classification, the PF model has a better classification performance than the CF model. Moreover, the HF model provides the best result among the three classifications models. Conclusions: The planomics features can be used for predicting and classifying the GPR results and for improving the model performance after combining the conventional features for the GPR classification.
Collapse
|
83
|
Liu Z, Liu C, Yao W, Gao S, Wang J, Zhang P, Ge H. Efficacy and safety of toripalimab combined with doxorubicin as first-line treatment for metastatic soft tissue sarcomas: an observational study. Anticancer Drugs 2021; 32:962-968. [PMID: 34001702 PMCID: PMC8448405 DOI: 10.1097/cad.0000000000001088] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2020] [Accepted: 04/20/2021] [Indexed: 11/25/2022]
Abstract
Programmed cell death protein 1 (PD-1) inhibitors have demonstrated promising activity among patients with advanced soft tissue sarcomas (STS) in phase II trials. The purpose of this study was to assess the efficacy and safety of toripalimab (a novel PD-1 inhibitor) combined with doxorubicin as first-line treatment in patients with metastatic STS between December 2018 and September 2019. A total of 30 patients with metastatic STS were included and followed up retrospectively. One patient had complete response (CR), 10 patients obtained partial response, and 13 patients achieved stable disease. The objective response rate was 36.7% and the disease control rate was 80%. The median progression-free survival (PFS) was 8 months (95% CI: 6.30-10.64). The most frequent any grade adverse events were nausea (66.7%), fatigue (60%), and vomiting (40%). Neutropenia (20%) was the most common grade 3/4 adverse events, followed by leucopenia (13.3%) and febrile neutropenia (6.7%). No death related to treatment was observed during the drugs administration. Toripalimab combined with doxorubicin is effective in patients with metastatic STS as first-line treatment with manageable adverse events.
Collapse
|
84
|
Zhen Q, Zhang Y, Yu Y, Yang H, Zhang T, Li X, Mo X, Li B, Wu J, Liang Y, Ge H, Xu Q, Chen W, Qian W, Xu H, Chen G, Bai B, Zhang J, Lu Y, Chen S, Zhang H, Zhang Y, Chen X, Li X, Jin X, Lin X, Yong L, Fang M, Zhao J, Lu Y, Wu S, Jiang D, Shi J, Cao H, Qiu Y, Li S, Kang X, Shen J, Ma H, Sun S, Fan Y, Chen W, Bai M, Jiang Q, Li W, Lv C, Li S, Chen M, Li F, Li Y, Sun L. Three Novel Structural Variations at MHC and IL12B Predisposing to Psoriasis. Br J Dermatol 2021; 186:307-317. [PMID: 34498260 DOI: 10.1111/bjd.20752] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/07/2021] [Indexed: 11/29/2022]
Abstract
BACKGROUND Structural variations (SVs, defined as DNA variants ≥50 bp) have been associated with various complex human diseases. However, research to screen the whole genome for SVs predisposing to psoriasis is still lacking. OBJECTIVES This study aimed to investigate the association of SVs and psoriasis. METHODS We performed a genome-wide screen on SVs using an imputation method on 5 independent cohorts with 45,386 subjects from the Chinese Han population. Fine mapping analysis, genetic interaction analysis and RNA expression analysis were conducted to explore the mechanism of SVs. RESULTS We obtained 4,535 SVs in total and identified 2 novel deletions (esv3608550, OR=2.73, P<2.00×10-308 ; esv3608542, OR=0.47, P=7.40×10-28 ) at 6q21.33 (MHC), 1 novel Alu element insertion (esv3607339, OR=1.22, P=1.18×10-35 ) at 5q33.3 (IL12B), and confirmed 1 previously reported deletion (esv3587563, OR=1.30, P=9.52×10-60 ) at 1q21.2 (LCE) for psoriasis. Fine mapping analysis including SNPs and small Insertions/Deletions (InDels) revealed that esv3608550 and esv3608542 were independently associated with psoriasis, and a novel independent SNP (rs9378188, OR=1.65, P=3.46×10-38 ) was identified at 6q21.33. By genetic interaction analysis and RNA expression analysis, we speculate that the association of 2 deletions at 6q21.33 with psoriasis might relate to their influence on the expression of HLA-C. CONCLUSIONS Our study constructed the most comprehensive SV map for psoriasis thus far and enriched the genetic architecture and pathogenesis of psoriasis as well as highlighted the nonnegligible impact of SVs on complex diseases.
Collapse
|
85
|
Li D, Wei S, Li T, Liu Y, Cai J, Ge H. Study of Spinal Cord Substructure Expansion Margin in Esophageal Cancer. Technol Cancer Res Treat 2021; 20:15330338211024559. [PMID: 34137317 PMCID: PMC8216358 DOI: 10.1177/15330338211024559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Purpose: To analyze the setup errors and residual errors of different spinal cord parts in esophageal cancer patients and to explore the necessity of spinal cord segmental expansion. Methods and Materials: Sixty cases of esophageal cancer were included with 20 patients subdivided into the following groups: neck, chest and abdomen as per the treatment site. The patients underwent intensity modulated radiation therapy (IMRT) between 2017 and 2019. Thermoplastic mask or vacuum bag were utilized for immobilization of different groups. CTVision (Siemens CT-On-Rail system) was used to acquire pre-treatment CT, and 20 consecutive pre-treatment CT datasets were collected for data analysis for each case. Images were exported to MIM (MIM Software Inc.) for processing and data analysis. Dice coefficient, maximum Hausdorff distance and centroid coordinate values between the spinal cord contours in the pre-treatment CTs and the planning CT were calculated and extracted. The contour expansion margin value is calculated as MPRV = 1.3 ∑ total + 0.5 σ total, where ∑ total and σ total are the systematic and random error, respectively. Results: For neck, chest, abdominal segments of the spinal cord, the mean Dice coefficients (± SD) are 0.73 ± 0.06, 0.80 ± 0.06, 0.82 ± 0.06, the maximum Hausdorff distance residual error (± SD) are 4.46 ± 0.55, 3.49 ± 0.53, 3.46 ± 0.69 mm, and the mean centroid coordinate residual error (± SD) are 2.40 ± 0.53, 1.66 ± 0.47, 2.14 ± 0.95 mm, respectively. The calculated margin using residual centroid method in medial-lateral (ML), anterior-posterior (AP), and cranial-caudal (CC) direction of spinal cord in neck, chest, abdominal segments are 3.86, 5.37, 6.36 mm, 3.45, 3.83, 4.51 mm, 4.05, 4.83, 7.06 mm, respectively, and the calculated margin using residual Hausdorff method are 3.10, 5.33 and 6.15 mm, 3.30, 3.77, 4.61 mm, 3.35, 4.76, 6.87 mm, respectively. Conclusion: The setup errors and residual errors are different in each segment of the spinal cord. Different margins expansion should be applied to different segment of spinal cord.
Collapse
|
86
|
Cao J, He Y, Cai W, Zhou W, Cong J, Tan R, Ge H, Pu D, Wu J. Analysis of the MCL-1 gene in Chinese women with idiopathic premature ovarian insufficiency. Climacteric 2021; 24:521-525. [PMID: 34008462 DOI: 10.1080/13697137.2021.1921727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
OBJECTIVE Animal studies have demonstrated that myeloid cell leukemia-1 (Mcl-1) gene deficiency leads to premature ovarian failure and decreased reproductive ability in mice. This study investigated the relationship between MCL-1 gene variation and idiopathic premature ovarian insufficiency (POI) in Chinese women. METHODS A total of 200 idiopathic POI patients and 100 healthy controls were recruited for this study, and peripheral blood was collected. First, genomic DNA was extracted from peripheral leukocytes. Then, the entire coding region and splice sites of the MCL-1 gene were amplified by polymerase chain reaction. Chi-squared tests were used to compare the genotype distribution and allele frequency of single nucleotide polymorphisms between the POI and control groups. RESULTS Three mutations of the MCL-1 gene (c.-36C > T, c.-131C > T and c.78C > T) were identified. After data analysis, c.-36C > T and c.-131C > T in the 5'-untranslated region were both found in the POI group and the control group. No difference was found in the genotype distribution or allelic frequency of either variant between the POI group and the control group (p > 0.05). The synonymous variant (c.78C > T) in exon 1 was discovered in only one of the control subjects and did not result in a change in amino acid sequence (p.Gly26Gly). CONCLUSION MCL-1 gene mutation may not be associated with idiopathic POI in Chinese women.
Collapse
|
87
|
Xu G, Bu S, Wang X, Ge H. Silencing the Expression of Cyclin G1 Enhances the Radiosensitivity of Hepatocellular Carcinoma In Vitro and In Vivo by Inducing Apoptosis. Radiat Res 2021; 195:378-384. [PMID: 33543294 DOI: 10.1667/rade-20-00180.1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2020] [Accepted: 12/30/2020] [Indexed: 11/03/2022]
Abstract
Radiotherapy plays an important role in the treatment of hepatocellular carcinoma (HCC). Cyclin G1 is a novel member of the cyclin family, and it is abnormally expressed in HCC. In this study we investigated the role of cyclin G1 in the radiotherapy of HCC cells. The expression of cyclin G1 was silenced by transfection of cyclin G1-siRNA into HepG2 cells and Huh7 cells, and the expression of cyclin G1 mRNA and protein was measured by qRT-PCR and Western blot analysis. The proliferation was analyzed using MTT assay, and the radiosensitivity of HCC cells was detected using colony formation assay and a xenograft tumor model. The expression of apoptosis-related proteins (Bcl-2 and Bax) was detected by Western blot analysis, and caspase-3 was detected using fluorimetry. The expression of cyclin G1 mRNA and protein in HepG2/Huh7-cyclin G1-siRNA cells was found to be significantly decreased compared to that in HepG2/Huh7 cells. Silencing the expression of cyclin G1 inhibited the proliferation of HCC cells and enhanced radiosensitivity in HCC cells in vitro and in vivo. Knockdown of cyclin G1 expression significantly decreased Bcl-2 expression, and increased Bax expression and caspase-3 activity in HCC cells. Silencing of cyclin G1 expression enhances the radiosensitivity of HCC cells in vitro and in vivo. The mechanism for this may be related to the regulation of apoptosis-related proteins.
Collapse
|
88
|
Zhang X, Zhang X, Du W, Dai L, Luo R, Fang Q, Ge H. Fine Needle Biopsy Versus Core Needle Biopsy Combined With/Without Thyroglobulin or BRAF 600E Mutation Assessment for Detecting Cervical Nodal Metastasis of Papillary Thyroid Carcinoma. Front Endocrinol (Lausanne) 2021; 12:663720. [PMID: 33912138 PMCID: PMC8072388 DOI: 10.3389/fendo.2021.663720] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Accepted: 03/10/2021] [Indexed: 11/13/2022] Open
Abstract
Objectives To analyze the diagnostic benefit of fine needle aspiration biopsy cytology (FNAB-C) and core needle biopsy tissue (CNB-T) with the addition of thyroglobulin (Tg) in the washout of the needle or BRAF V600E mutation assessment in assessing cervical lymph node metastasis (LNM) in papillary thyroid carcinoma. Materials and Methods A total of 186 lymph nodes were punctured by fine or core needle. The diagnostic performance of FNAB-C and CNB-T with Tg in the washout or BRAF V600E mutation assessment was compared. Results The optimal cutoff value of FNAB-Tg was 1.0 ng/ml, with an AUC of 0.976. The sensitivity and specificity of FNAB-C in predicting cervical LNM were 97.4% and 71.4%, respectively, and the addition of FNAB-Tg could contribute to a sensitivity of 100% and a specificity of 95%, but the introduction of BRAF V600E mutation assessment was associated with a decreased sensitivity of 96.3% and a decreased specificity of 50.0%. The FNAB-Tg level showed a comparable distribution in malignant lymph nodes with different TgAb statuses, serum TSH levels, and serum Tg levels. The sensitivity and specificity of CNB-T in predicting cervical LNM were 98.9% and 100%, respectively. The addition of CNB-Tg did not alter the diagnostic ability, but the introduction of BRAF V600E mutation assessment obtained the best performance, with a sensitivity of 100% and specificity of 100%. Conclusion The sensitivity and specificity of FNAB-C could be increased if combined with FNAB-Tg. CNB-T alone could provide satisfactory diagnostic reliability.
Collapse
|
89
|
Lv D, Lin L, Wu X, Yan S, Ge H, Yan Z, Wang G. P76.99 Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
90
|
Bi N, Xu K, Ge H, Chen M, E M, Zhang L, Cao J, Zhang X, Ding X, Xia B, Zhao L, Han L, Li J, Hu C, Wang L. OA02.06 PSM Analysis Results from REFRACT: A Multi-Center Cohort Study Investigating the Treatment Patterns in EGFR-Mutant Unresectable LA- NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
91
|
Brauner JM, Mindermann S, Sharma M, Johnston D, Salvatier J, Gavenčiak T, Stephenson AB, Leech G, Altman G, Mikulik V, Norman AJ, Monrad JT, Besiroglu T, Ge H, Hartwick MA, Teh YW, Chindelevitch L, Gal Y, Kulveit J. Inferring the effectiveness of government interventions against COVID-19. Science 2021; 371:eabd9338. [PMID: 33323424 PMCID: PMC7877495 DOI: 10.1126/science.abd9338] [Citation(s) in RCA: 505] [Impact Index Per Article: 168.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2020] [Revised: 09/25/2020] [Accepted: 12/08/2020] [Indexed: 12/14/2022]
Abstract
Governments are attempting to control the COVID-19 pandemic with nonpharmaceutical interventions (NPIs). However, the effectiveness of different NPIs at reducing transmission is poorly understood. We gathered chronological data on the implementation of NPIs for several European and non-European countries between January and the end of May 2020. We estimated the effectiveness of these NPIs, which range from limiting gathering sizes and closing businesses or educational institutions to stay-at-home orders. To do so, we used a Bayesian hierarchical model that links NPI implementation dates to national case and death counts and supported the results with extensive empirical validation. Closing all educational institutions, limiting gatherings to 10 people or less, and closing face-to-face businesses each reduced transmission considerably. The additional effect of stay-at-home orders was comparatively small.
Collapse
|
92
|
Brauner JM, Mindermann S, Sharma M, Johnston D, Salvatier J, Gavenčiak T, Stephenson AB, Leech G, Altman G, Mikulik V, Norman AJ, Monrad JT, Besiroglu T, Ge H, Hartwick MA, Teh YW, Chindelevitch L, Gal Y, Kulveit J. Inferring the effectiveness of government interventions against COVID-19. Science 2021; 371:science.abd9338. [PMID: 33323424 DOI: 10.1101/2020.05.28.20116129] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2020] [Revised: 09/25/2020] [Accepted: 12/08/2020] [Indexed: 05/21/2023]
Abstract
Governments are attempting to control the COVID-19 pandemic with nonpharmaceutical interventions (NPIs). However, the effectiveness of different NPIs at reducing transmission is poorly understood. We gathered chronological data on the implementation of NPIs for several European and non-European countries between January and the end of May 2020. We estimated the effectiveness of these NPIs, which range from limiting gathering sizes and closing businesses or educational institutions to stay-at-home orders. To do so, we used a Bayesian hierarchical model that links NPI implementation dates to national case and death counts and supported the results with extensive empirical validation. Closing all educational institutions, limiting gatherings to 10 people or less, and closing face-to-face businesses each reduced transmission considerably. The additional effect of stay-at-home orders was comparatively small.
Collapse
|
93
|
Liu Z, Yao W, Zhao Y, Liu O, Zhang P, Ge H. Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas. Cancer Manag Res 2021; 13:1009-1016. [PMID: 33574700 PMCID: PMC7871875 DOI: 10.2147/cmar.s286322] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2020] [Accepted: 01/05/2021] [Indexed: 11/23/2022] Open
Abstract
Purpose Anlotinib is a novel tyrosine kinase inhibitor with promising anti-tumor activity in patients with advanced soft tissue sarcomas (STS) in China. Liposomal doxorubicin monotherapy showed an encouraging effect on this disease. The aim of this study was to evaluate the efficacy and safety of anlotinib combined with liposomal doxorubicin followed by anlotinib maintenance in patients with metastatic STS. Patients and Methods This is a multicenter, retrospective, observational study. We reviewed 27 patients with metastatic STS from July 2018 to December 2019, who were treated with anlotinib combined with liposomal doxorubicin followed by anlotinib maintenance in the absence of the tumor progression or intolerable adverse events (AEs). Results Of the 27 patients included, 2 patients had complete response (CR), 9 patients obtained partial response (PR), 11 patients achieved stable disease (SD). The objective response rate was 40.7%, the disease control rate was 81.5%, and the median progression-free survival (PFS) was 7 months (95% CI, 5.3–8.1 months). The progression-free rate (PFR) at 3 and 6 months was 81.5% and 59.3%, respectively. Most AEs were mild and acceptable. The most frequent grade 3/4 AEs were leukopenia (33.3%), febrile neutropenia (7.4%), and anemia (7.4%). No deaths related to the treatment were reported. Conclusion This study shows that anlotinib combined with liposomal doxorubicin followed by anlotinib maintenance is effective in patients with metastatic STS, and most AEs of this combined therapy are mild and acceptable. Further investigation on its efficacy is warranted.
Collapse
|
94
|
Zheng X, Sun Y, Ye K, Fan C, Wang X, Yang Y, Jiao R, Ge H. Stereotactic ablative radiotherapy as single treatment for early stage non-small cell lung cancer: A single institution analysis. Thorac Cancer 2021; 12:899-905. [PMID: 33529496 PMCID: PMC7952798 DOI: 10.1111/1759-7714.13768] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2020] [Revised: 11/15/2020] [Accepted: 11/17/2020] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND Stereotactic ablative radiotherapy (SABR) is the current standard-of-care in cases of inoperable early stage non-small cell lung cancer (ES-NSCLC). This study aimed to assess the survival outcomes and recurrence patterns after SABR for ES-NSCLC in a hospital setting. METHODS A single-institution retrospective study was performed which included 109 patients who had undergone SABR. The main study endpoints were overall survival (OS), cancer specific survival (CSS), local recurrence-free survival (LRFS), regional recurrence free survival (RRFS) and distant metastasis-free survival (DMFS). Univariate and multivariate analysis were conducted to explore the potential factors which might be related to patient survival. RESULTS A total of 109 patients were enrolled into the study. Median follow-up was 44 months (range: 2-93 months). (i) Recurrence results: Among 45 patients with recurrence, 30 patients (28%) had distant metastasis (DM), 17 patients (16%) had local recurrence (LR), 10 patients (9%) had regional recurrence (RR) of lymph nodes and two patients (2%) had second primary lung cancer (SPLC). (ii) Survival results: Median OS, CSS, PFS was 78 months, 78 and 40 months. Two-year OS, CSS, PFS, LRFS, RRFS and DMFS was 84.7%, 87.1%, 69.2%, 86.8%, 92.7% and 78.0%, respectively. Four-year OS, CSS, PFS, LRFS, RRFS and DMFS was 55.6%, 60.7%, 37.3%, 76.3%, 88.4% and 59.4%, respectively. (iii) Univariate and multivariate analyses indicated that age was a prognostic factor of CSS in patients aged <75 years (P = 0.04 HR 2.12 95% confidence interval [CI]: 1.04-4.33). CONCLUSIONS Although high survival rates can be achieved in ES-NSCLC patients treated with SABR, using SABR on its own may not be enough. Prolonged surveillance and adjuvant therapy is therefore needed.
Collapse
|
95
|
Zhang Y, Wang J, Yu Z, Ge H, Zhang LW, Feng LX. Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations. Clin Transl Sci 2021; 14:890-897. [PMID: 33382908 PMCID: PMC8212732 DOI: 10.1111/cts.12951] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2019] [Revised: 11/04/2020] [Accepted: 11/06/2020] [Indexed: 12/18/2022] Open
Abstract
Abstract To explore a better treatment strategy for patients with advanced non‐small cell lung cancer harboring sensitive epidermal growth factor receptor mutations, a total of 271 patients were retrospectively analyzed. The patients were divided into two groups: the combination group (58 cases), which received concurrent icotinib, pemetrexed, and platinum treatment, and the sequential group (213 cases), which received the sequential pemetrexed and platinum therapy, followed by icotinib treatment. The primary end points were progression‐free survival (PFS) and PFS on the subsequent line of therapy (PFS2). PFS in the combination group was significantly higher compared with that in the sequential group (16.89 months vs. 9.90 months; p < 0.001). PFS in the combination group was also significantly higher than PFS2 in the sequential group (16.89 months vs. 14.05 months; p = 0.009). The overall survival (OS) of the patients was 33.22 months (95% confidence interval (CI): 26.99–37.01) in the combination group and 26.47 months (95% CI: 25.05–26.95) in the sequential group (p < 0.001). The combination group’s objective response rate was superior to that of the sequential group (79.31% vs. 52.11%; p < 0.001). Propensity score matching also revealed that icotinib therapy combined with chemotherapy extended the PFS, PFS2, and OS of the patients (p < 0.0001, p = 0.003, and p = 0.001, respectively). The combination group’s objective response rate was also better compared with the sequential group (79.31% vs. 51.72%; p = 0.001). In conclusion, our study demonstrated icotinib combined with chemotherapy can improve survival efficacy better than the separated two‐line therapy. Study Highlights WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
For advanced non‐small cell lung cancer (NSCLC) harboring activating EGFR mutants, EGFR‐tyrosine kinase inhibitors (TKIs) are the standard first‐line treatment. Unfortunately, most patients with NSCLC harboring EGFR mutations acquire EGFR‐TKI resistance after EGFR‐TKI treatment for about 10–14 months. Studies have indicated that chemotherapy plus EGFR‐TKIs may have combined effects on the growth of NSCLC cells. However, until now, there has been no study comparing the concurrent and sequential EGFR‐TKIs plus chemotherapy.
WHAT QUESTION DID THIS STUDY ADDRESS?
We retrospectively analyzed the efficacy and safety of concurrent versus sequential icotinib and chemotherapy in untreated NSCLC with sensitive EGFR mutations.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
In the patients with NSCLC with sensitive EGFR mutations, the first‐line pemetrexed plus platinum combined with icotinib better improved PFS, PFS2, and objective response rate compared with first‐line icotinib and second‐line pemetrexed plus platinum.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?
The results of this paper provide guidance for the strategy choice in the treatment of patients with NSCLC.
Collapse
|
96
|
Zhang X, Chen W, Fang Q, Fan J, Feng L, Guo L, Liu S, Ge H, Du W. Lateral Lymph Node Metastases in T1a Papillary Thyroid Carcinoma: Stratification by Tumor Location and Size. Front Endocrinol (Lausanne) 2021; 12:716082. [PMID: 34335480 PMCID: PMC8320373 DOI: 10.3389/fendo.2021.716082] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Accepted: 06/25/2021] [Indexed: 01/17/2023] Open
Abstract
OBJECTIVE To analyze the incidence and risk factors for lateral lymph node metastases (LNMs) in T1a papillary thyroid carcinoma (PTC) with a focus on tumor location and size. MATERIALS AND METHODS The incidence of lateral LNM in 345 cases of T1a PTC was retrospectively analyzed. Univariate and multivariate analyses were performed to assess the relationships between lateral LNM and clinicopathological characteristics. RESULTS The incidence of skip metastasis to lateral LNM in T1a PTC located in the upper lobe was 12.1% (8/66). Logistic regression analysis indicated tumor size >5 mm (OR = 5.04, 95% CI = 1.79 to 14.18, P = 0.002), upper lobe location (OR = 7.68, 95% CI = 3.05-19.34, P < 0.001) and the number of central neck LNM (<2: OR = 24.79, 95% CI = 8.23-74.60, P < 0.001; ≥2: OR = 4.99, 95% CI = 1.95-12.73, P < 0.001) were independently associated with lateral LNM. Comparing the lateral and central LNM stratification based on tumor location revealed that both the incidences of lateral (33.3%) and central (30.3%) LNM of T1a PTC located in the upper lobe were higher than those of T1a PTC located in the middle and lower lobes. Of T1a PTC located in the upper lobe, the incidence of lateral LNM was 33.3% (22/66), which was higher than that [30.3% (20/66)] of central LNM. This finding is reversed in all T1a PTC cases and T1a PTC cases with tumor located in the middle and lower lobes. CONCLUSION A particularly high likelihood of lateral LNM was observed in T1a PTC patients with tumor located in the upper lobe of the thyroid gland, especially the tumor >5 mm in size, which could be considered a risk factor for lateral LNM in the clinical management of T1a PTC.
Collapse
|
97
|
Su H, Peng LH, Sun G, Yang YS, Wu J, Jiang GJ, Ge H. Effect of different body position on anorectal manometry for chronic constipation patients. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2020; 23:8493-8500. [PMID: 31646580 DOI: 10.26355/eurrev_201910_19162] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE To analyze the different influence of body position on wireless high-resolution anorectal manometry parameters and in classification for chronic constipation patients. PATIENTS AND METHODS Fifty consecutive patients with chronic constipation and 20 healthy volunteers were included in this study, all of whom accepted the Rome IV constipation questionnaires, underwent rectal balloon expulsion test and wireless high-resolution anorectal manometry. The wireless high-resolution anorectal manometry was performed in the left lateral, seated, and squatting positions for every study subject. The Statistical Product and Service Solutions (SPSS) 21.0 software (IBM Corp., Armonk, NY, USA) was used for statistical analysis. RESULTS The anal sphincter resting pressure, anal sphincter squeezing pressure, and rectal internal pressure during the evacuation in the seated position and squatting position were significantly higher than those in the left lateral position in both the volunteer group and patient group, without a significant difference between the seated position and squatting position. The initial perception threshold was higher in the patient group than in the volunteer group. The wireless high-resolution anorectal manometry in different positions combined with the rectal balloon expulsion test mainly affects the diagnosis of the subtype of inadequate defecatory propulsion. CONCLUSIONS Compared with the left lateral position test, the wireless high-resolution anorectal manometry in the seated position and squatting positions is more consistent with the human physiological bowel condition, and the result of the test can be affected by the body position. The wireless high-resolution anorectal manometry can differentiate between subtypes during the diagnosis of inadequate defecatory propulsion.
Collapse
|
98
|
Wang C, Li H, Chen Y, Ge H. Local failure patterns after radical resection and adjuvant chemotherapy in patients with pN2 nonsmall-cell lung cancer: A retrospective analysis. Indian J Cancer 2020; 57:323-329. [PMID: 32769295 DOI: 10.4103/ijc.ijc_691_18] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background The patterns of local failure in stage pN2 nonsmall-cell lung cancer (NSCLC) patients undergoing radical resection and adjuvant chemotherapy are controversial. Methods The sites of local failure were compared in subgroups of patients with relevant clinicopathologic features (e.g., location and size of primary lesions). Results Totally 75 patients with local failure after radical resection and adjuvant chemotherapy for pN2 NSCLC were included in the analysis. Thirty-seven (49.3%) patients had distant metastasis. The median duration from surgical resection to local failure was 11 months (range: 3-45 months). Sites with ≥10% failure rate in all subgroups based on the location of the primary lesions included 4R, 7, the ipsilateral hilum, and the stump. Additional sites with ≥10% failure rate included 2R, 2L, 4L, and 5 for lesions in the left upper lobe; 4L and 5 for lesions in the left lower lobe; and 2R and 3P for lesions in the right upper-middle lobe. Squamous cell carcinoma affected the stump failure rate compared to adenocarcinoma (56.3% vs. 18.0%, P = 0.003). Tumor diameter ≥5 cm affected the stump failure rate compared to tumor diameter < 5 cm (44.0% vs. 18.0%, P = 0.016). Skip N2 metastasis affected the ipsilateral hilum failure rate compared to nonskip N2 metastasis (7.5% vs. 31.4%, P = 0.008). Conclusions For pN2 NSCLC patients undergoing radical resection and adjuvant chemotherapy, different lung lobes had different high-risk failure sites. Left lung cancer is prone to bilateral mediastinal lymph nodes recurrence, while right lung cancer mainly recurs with ipsilateral mediastinal lymph nodes. Moreover, the local failure patterns are influenced by pathological type, tumor size, and skip N2 metastasis.
Collapse
|
99
|
Yang Y, Luo H, Zheng XL, Ge H. The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clin Transl Oncol 2020; 23:1117-1127. [PMID: 33211281 DOI: 10.1007/s12094-020-02502-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2020] [Accepted: 09/15/2020] [Indexed: 12/26/2022]
Abstract
BACKGROUND Immune checkpoint inhibitors (ICIs) plus chemotherapy (CT) have strikingly expanded the therapeutic landscape for advanced non-small cell lung cancer (NSCLC), but little is known about which is superior. We performed a meta-analysis that compared the efficacy and safety of PD-1 inhibitor + CT with PD-L1 inhibitor + CT. METHODS PubMed, Embase, Web of Science, Cochrane Library, and major international scientific meetings were searched for relevant randomized controlled trials (RCTs), and the indirect analysis was performed for PD-1 + CT vs PD-L1 + CT. The outcomes included progression-free survival (PFS), overall survival (OS), objective response rate (ORR) and treatment-related adverse events (TRAEs). RESULTS 8 phase III RCTs with 4253 patients comparing PD-1/PD-L1 + CT in NSCLC were included. The PD-1 + CT led to notably longer OS most in low/negative expression of PD-L1 for NSCLC patients compared with PD-L1 + CT. In terms of Grade 3-5 TRAEs, the results showed that PD-1 + CT and PD-L1 + CT exclusively increased the risk of adverse incidence than CT alone, especially for PD-L1 + CT (p < 0.00001). For subgroups including female, young patients, patients with nonsmoker, and EGFR/ALK wild-type, PD-1 + CT was associated with prolonged OS (p < 0.05). Meanwhile, for no liver metastasis of NSCLC patients, we found obviously OS advantage for patients treated with PD-1 + CT compared to PD-L1 + CT. CONCLUSIONS ICIs + CT seemed to be more effective first-line regimen and PD-1 + CT could be recommended as the first-rank therapy for advanced NSCLC patients with low/negative expression of PD-L1. However, we should be particularly vigilant about the occurrence of the Grade 3-5 TRAEs.
Collapse
|
100
|
Luo H, Laster K, Beggs J, Jia X, Wang L, Ge H. Disulfiram Copper Complex Enhancing the Radiation Sensitivity and Immunogenicity of Esophageal Cancer Cells. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.1653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|